- May 20, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Miostat, Carbastat, Carboptic
Synonyms :
Class :
cholinergic agonists and Ophthalmic glaucoma agents
Brand Name :
Miostat, Carbastat, Carboptic
Synonyms :
Class :
cholinergic agonists and Ophthalmic glaucoma agents
Dosage Forms & Strengths
Topical solution
1.5%
3%
Intraocular solution
0.01%
Instill not more than 0.5 ml into the anterior chamber during surgery
Instill not more than 0.5 ml into the anterior chamber during surgery
Dosage Forms & Strengths
Topical solution
1.5%
3%
Intraocular solution
0.01%
Instill not more than 0.5 ml into the anterior chamber during surgery
Instill not more than 0.5 ml into the anterior chamber during surgery
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
it may increase the risk of adverse effects of cholinergic agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may decrease the toxic effect of beta blockers
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may increase the toxic effect of anti-cholinergic agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
Adverse drug reactions:
Frequency Not Defined
Corneal clouding
Bullous keratopathy
Persistent bullous keratopathy
Retinal detachment
Abdominal cramps
Postoperative iritis following cataract extraction
Epigastric distress
Flushing
Arrhythmia
Hypotension
Syncope
Epigastric stress
Salivation
Headache
Sweating
Tightness in urinary bladder
Vomiting
Asthma
Diaphoresis
Pregnancy warnings:
AU TGA pregnancy category: B2
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: carbachol (Rx)
Pronunciation: KAR-ba-kall
Why do we use carbachol?
carbachol is an ophthalmic glaucoma agent which is used to treat intraocular pressure in the eye